These studies provide evidence for yet another mechanism of the NAFLD-ameliorating GLP1-RA pharmacologic properties, contributing to a plethora of other evidence supporting the role of GLP-1RAs in the treatment of NAFLD. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.